Original language | English |
---|---|
Pages (from-to) | 365-366 |
Number of pages | 2 |
Journal | Cardiovascular Drugs and Therapy |
Volume | 25 |
Issue number | 4 |
DOIs |
|
Publication status | Published - 2011 Aug |
ASJC Scopus subject areas
- Pharmacology
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Erratum : Design and rationale of japanese evaluation between formula of azelnidipine and amlodipine add on olmesartan to get antialbuminuric effect study (J-FLAG) : Ion of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria (Cardiovascular Drugs and Therapy (2011) 25 (365366) DOI 10.1007/s10557-011-6309-5)). / Ando, Katsuyuki; Haneda, Masakazu; Ito, Sadayoshi; Kashihara, Naoki; Node, Koichi; Nangaku, Masaomi; Shimosawa, Tatsuo; Kishimoto, Junji; Fujita, Toshiro.
In: Cardiovascular Drugs and Therapy, Vol. 25, No. 4, 08.2011, p. 365-366.Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Erratum
T2 - Design and rationale of japanese evaluation between formula of azelnidipine and amlodipine add on olmesartan to get antialbuminuric effect study (J-FLAG) : Ion of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria (Cardiovascular Drugs and Therapy (2011) 25 (365366) DOI 10.1007/s10557-011-6309-5))
AU - Ando, Katsuyuki
AU - Haneda, Masakazu
AU - Ito, Sadayoshi
AU - Kashihara, Naoki
AU - Node, Koichi
AU - Nangaku, Masaomi
AU - Shimosawa, Tatsuo
AU - Kishimoto, Junji
AU - Fujita, Toshiro
PY - 2011/8
Y1 - 2011/8
UR - http://www.scopus.com/inward/record.url?scp=80052280847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052280847&partnerID=8YFLogxK
U2 - 10.1007/s10557-011-6315-7
DO - 10.1007/s10557-011-6315-7
M3 - Comment/debate
AN - SCOPUS:80052280847
VL - 25
SP - 365
EP - 366
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
SN - 0920-3206
IS - 4
ER -